Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average volume of 165 put options.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on XENE. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $57.38.
View Our Latest Stock Analysis on XENE
Insider Activity at Xenon Pharmaceuticals
Hedge Funds Weigh In On Xenon Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at approximately $63,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Xenon Pharmaceuticals by 17.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 191,852 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 29,169 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at approximately $1,566,000. Vident Advisory LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at approximately $212,000. Finally, Two Sigma Advisers LP raised its position in shares of Xenon Pharmaceuticals by 9.1% in the 4th quarter. Two Sigma Advisers LP now owns 298,700 shares of the biopharmaceutical company’s stock valued at $11,709,000 after purchasing an additional 25,000 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Stock Performance
Shares of NASDAQ:XENE opened at $37.17 on Thursday. The company has a market cap of $2.85 billion, a P/E ratio of -13.18 and a beta of 1.26. Xenon Pharmaceuticals has a one year low of $33.27 and a one year high of $47.44. The business’s 50-day simple moving average is $39.15 and its 200 day simple moving average is $40.27.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. Analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Recommended Stories
- Five stocks we like better than Xenon Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Retail Stocks Investing, Explained
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What Are Growth Stocks and Investing in Them
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.